Clinical Trials Browser

Terminated × Lymphoma, Follicular × umbralisib × Clear all

NCT03919175 2026-02-27

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Terminated

18 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03828448 2023-07-24

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Phase 2 Terminated

34 enrolled 2 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02793583 2022-07-21

UNITY-NHL

Phase 2/3 Terminated

710 enrolled 2 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03178201 2021-07-16

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Phase 2 Terminated

5 enrolled 5 charts

Lymphoid

Lymphoma, Follicular